Your browser doesn't support javascript.
loading
The protective effects of pediatric vaccination on multisystem inflammatory syndrome in children stratified by vaccine status, types and virus variants.
Zhang, Yan Fang; Xia, Cai Yun; Yang, Qian; Cai, Ying; Li, Dao Ting; Jiang, Qi; Hu, Peng.
Afiliação
  • Zhang YF; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Xia CY; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Yang Q; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Cai Y; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Li DT; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Jiang Q; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Hu P; Department of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Electronic address: hupeng28@aliyun.com.
Int Immunopharmacol ; 125(Pt A): 111105, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38149578
ABSTRACT

BACKGROUND:

Few studies highlight the stratification of COVID-19 vaccine effectiveness on MIS-C according to vaccine status, types and SARS-COV-2 variants.

METHODS:

A web-based analysis was conducted through searches of PubMed, Web of Science and Medline databases from January 1, 2020, to May 16, 2023. The search terms used were (multisystem inflammatory syndrome in children OR MIS-C OR PIMS OR PIMS-TS) AND (COVID-19 OR SARS-CoV-2) AND (vaccine OR vaccination) AND (children OR adolescents OR pediatric).

RESULTS:

6701 children from 13 studies met the MIS-C definition. 92.1 % (1332/1446) of MIS-C cases were unvaccinated, whereas partial vaccination and full vaccination were 3.7 % (54/1446) and 4.2 % (60/1446)respectively. In the two studies encompassing 41 vaccinated MIS-C cases, 34 (82.9 %) received BNT162b2, 2 (4.9 %) received mRNA-1273, 4 (9.8 %) received Sinovac vaccine, and only one received a heterologous primary-boost regimen. Among 838 vaccinated MIS-C cases with different SARS-COV-2 variants, 23(2.8 %) were infected by the Wild-type, 80(9.5 %) by the Alpha variant, 521(62.2 %) by the Delta variant, and 214(25.5 %) by the Omicron variant. A significant difference was observed in vaccination rates among MIS-C cases across different variant pandemics (χ2 = 37.79, P < 0.001). The highest vaccination rate (26.3 %) occurred in the Alpha predominant period, thereafter dropped to 5.0 % in the Delta predominant period, and then increased to 12.6 % in the Omicron predominant period.

CONCLUSIONS:

Heterologous vaccination might provide a slightly more protective effect than homologous manner for MIS-C. As the virus mutates over time, its pathogenicity to MIS-C degrades among vaccinated individuals.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Tecido Conjuntivo / COVID-19 Limite: Adolescent / Child / Humans Idioma: En Revista: Int Immunopharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Tecido Conjuntivo / COVID-19 Limite: Adolescent / Child / Humans Idioma: En Revista: Int Immunopharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China